THE Federal Health Minister Mark Butler announced the PBS listing of Australia's first combined anti-programmed cell death protein 1 (PD-1)/anti-lymphocyte-activation gene 3 (LAG-3) treatment for adult and paediatric patients aged 12 years or older with unresectable or metastatic melanoma, effective 01 Feb, at a morning press conference held at The Queen Elizabeth Hospital, Adelaide, yesterday.
Bristol Myers Squibb's Opdualag (nivolumab/relatlimab) is a fixed-dose combination of nivolumab, a PD-1 inhibitor, and relatlimab, a novel first-in-class lymphocyte-activation gene LAG-3-blocking antibody, which restores the effector function of exhausted T-cells and promotes antitumour activity.
Co-Medical Director of Melanoma Institute Australia, and 2024 NSW Australian of the Year, Prof Georgina Long, said, "inhibiting LAG-3 with relatlimab, in combination with nivolumab, gives us a new treatment to add to our toolkit against melanoma".
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jan 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jan 24
